orbofiban has been researched along with Myocardial Infarction in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (95.00) | 29.6817 |
| 2010's | 1 (5.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cannon, CP; Cox, D; Fitzgerald, DJ; Jneid, H; Maree, AO; Ryan, J; Shields, DC; Vangjeli, C | 1 |
| Fitzgerald, A; Fitzgerald, DJ; Muckian, C; O'Byrne, A; O'Neill, A; Shields, DC | 1 |
| Bentley, JH; Cannon, CP; Charlesworth, A; Kovar, D; Rogers, WJ | 1 |
| Braunwauld, E; Cannon, CP; Cantor, WJ; Charlesworth, A; Goodman, SG; Langer, A; Murphy, SA | 1 |
| Abernethy, DR; Cox, D; Fitzgerald, DJ; Mager, DE; Shirey, JD | 1 |
| Cannon, CP; Feske, SK; Murphy, S; Schwamm, LH; Smith, EE | 1 |
| Buros, JL; Cannon, CP; de Lemos, JA; Morrow, DA; Murphy, SA; O'Donoghue, M; Sabatine, MS | 1 |
| Aster, RH; Brassard, J; Braunwald, E; Cannon, CP; Charlesworth, A; Cooper, R; McCabe, CH; Scirica, BM; Skene, AM | 1 |
| Braunwald, E; Cannon, CP; de Lemos, JA; McCabe, CH; Morrow, DA; Murphy, S; Rifai, N; Sabatine, MS; Scirica, BM; Wiviott, SD | 1 |
| Alexander, JC; Anders, RJ; Berink, P; Braunwald, E; Cannon, CP; Caspi, A; Charlesworth, A; Langer, A; Lopez-Sendon, J; McCabe, CH; Skene, A; Toman, J; Wilcox, RG | 1 |
| Jang, IK; Sabatine, MS | 1 |
| McGuire, DK; Newby, LK | 1 |
| Bhatt, DL; Topol, EJ | 1 |
| Cox, D; Crean, P; Fitzgerald, DJ; Quinn, M; Smith, R; Theroux, P | 1 |
| Cannon, CP | 1 |
| Bhatt, DL; Chew, DP; Sapp, S; Topol, EJ | 1 |
| Bentley, JH; Braunwald, E; Cannon, CP; McCabe, CH; Wilcox, RG | 1 |
| Anders, R; Burns, D; Kleiman, J; Nicholson, N; Wazowicz, B | 1 |
| Braunwald, E; Cannon, CP; Fitzgerald, A; Fitzgerald, DJ; O'Connor, FF; Shields, DC | 1 |
| Byrne, CE; Cannon, CP; Fitzgerald, AP; Fitzgerald, DJ; Kenny, D; Moran, B; Muckian, C; O'Neill, PA; Shields, DC | 1 |
5 review(s) available for orbofiban and Myocardial Infarction
| Article | Year |
|---|---|
The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Alanine; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Tirofiban; Tyrosine | 2000 |
Oral platelet glycoprotein IIb/IIIa inhibition.
Topics: Alanine; Angina, Unstable; Aspirin; Benzamidines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Myocardial Infarction; Oximes; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Syndrome; Treatment Outcome | 2000 |
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Acute Disease; Alanine; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Drug Therapy, Combination; Eptifibatide; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Tirofiban; Tyrosine | 2000 |
Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.
Topics: Administration, Oral; Alanine; Aspirin; Benzamidines; Clinical Trials, Phase III as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemorrhage; Humans; Incidence; Multicenter Studies as Topic; Myocardial Infarction; Oximes; Piperidines; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic | 2001 |
Xemilofiban/orbofiban: insight into drug development.
Topics: Alanine; Angina, Unstable; Animals; Benzamidines; Bleeding Time; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Coronary Thrombosis; Drug Evaluation, Preclinical; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines | 2001 |
11 trial(s) available for orbofiban and Myocardial Infarction
| Article | Year |
|---|---|
Genetic variability in the extracellular matrix as a determinant of cardiovascular risk: association of type III collagen COL3A1 polymorphisms with coronary artery disease.
Topics: Alanine; Alleles; Angina, Unstable; Collagen; Collagen Type III; Coronary Disease; Cross-Sectional Studies; Extracellular Matrix; Gene Frequency; Genetic Predisposition to Disease; Genotype; Hemorrhage; Heterozygote; Humans; Minisatellite Repeats; Myocardial Infarction; Myocardial Ischemia; Placebos; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Pyrrolidines; Treatment Outcome | 2002 |
Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial.
Topics: Aged; Alanine; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Coronary Angiography; Coronary Artery Bypass; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Pyrrolidines; Risk Factors; Stents; Survival Analysis | 2005 |
Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Cerebral Hemorrhage; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Ischemic Attack, Transient; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Proportional Hazards Models; Pyrrolidines; Risk Factors; Stroke; Syndrome; Thrombolytic Therapy | 2006 |
Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes.
Topics: Acute Disease; Adult; Alanine; Biomarkers; Fatty Acid-Binding Proteins; Female; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Natriuretic Peptide, Brain; Odds Ratio; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Pyrrolidines; Risk Factors; Troponin I | 2006 |
Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Thrombocytopenia; Thrombosis | 2006 |
Clinical application of C-reactive protein across the spectrum of acute coronary syndromes.
Topics: Acute Disease; Aged; Alanine; Angina Pectoris; Angina, Unstable; C-Reactive Protein; Coronary Disease; Female; Follow-Up Studies; Heart Failure; Humans; Male; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Recurrence; Risk; Syndrome | 2007 |
Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
Topics: Administration, Oral; Alanine; Anticoagulants; Aspirin; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heparin; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Stroke; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2000 |
Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes.
Topics: Acute Disease; Aged; Alanine; Angina, Unstable; Female; Humans; Male; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines | 2000 |
Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators.
Topics: Aged; Alanine; Angina, Unstable; Female; Follow-Up Studies; Humans; Leukocyte Count; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrrolidines; Risk Factors; Survival Rate | 2001 |
Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes.
Topics: Aged; Alanine; Angina, Unstable; Antigens, Human Platelet; Aspirin; Double-Blind Method; Female; Genetic Variation; Genotype; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Placebos; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Pyrrolidines | 2001 |
The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists.
Topics: Alanine; Coronary Disease; Genotype; Glycoproteins; Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Pyrrolidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; Stroke; Thrombosis; Treatment Outcome | 2002 |
4 other study(ies) available for orbofiban and Myocardial Infarction
| Article | Year |
|---|---|
G-protein beta3 subunit polymorphism and bleeding in the orbofiban in patients with unstable coronary syndromes-thrombolysis in myocardial infarction 16 trial.
Topics: Alanine; Heart Diseases; Heterotrimeric GTP-Binding Proteins; Humans; Myocardial Infarction; Polymorphism, Genetic; Pyrrolidines; Thrombolytic Therapy | 2010 |
Does initial and delayed heart rate predict mortality in patients with acute coronary syndromes?
Topics: Acute Disease; Alanine; Female; Heart Rate; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Prognosis; Pyrrolidines; Syndrome | 2004 |
Mapping the dose-effect relationship of orbofiban from sparse data with an artificial neural network.
Topics: Alanine; Angina, Unstable; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Neural Networks, Computer; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Reproducibility of Results | 2005 |
Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials.
Topics: Alanine; Angina, Unstable; Benzamidines; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Syndrome; Treatment Outcome | 2000 |